Search

Your search keyword '"Domingo Barber Hernández"' showing total 6 results
Start Over Author "Domingo Barber Hernández"
Sorry, I don't understand your search. ×
6 results on '"Domingo Barber Hernández"'

1. COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics - EAACI recommendations

Author

Hans Jürgen Hoffmann, Andrea Matucci, Anna Kosowska, Aslı Gelincik, Luis Perez de Llano, Oliver Pfaar, Mario Cazzola, Kari Nadeau, Milena Sokolowska, Alessandra Vultaggio, Eva Untersmayr, Oscar Palomares, Jean-Christoph Roger J-P Caubet, Anna Sediva, Isabel Skypala, Rosan Meyer, Davide Firinu, Montserrat Fernandez-Rivas, Sevim Bavbek, Ronald van Ree, Thomas Eiwegger, Domingo Barber Hernández, Alexia Chatzipetrou, Jonathan Corren, Elizabeth Palmer, Musa Khaitov, Mohamed H. Shamji, Vera Mahler, Oliver Price, Vibeke Backer, Magdalena Zemelka-Wiacek, Cezmi A. Akdis, Florin-Dan Popescu, Margitta Worm, Victoria Del Pozo, Alberto Alvarez-Perea, Annick Barbaud, Sylwia Smolinska, Karin Hoffmann-Sommergruber, Job van Boven, Audrey DunnGalvin, Motohiro Ebisawa, Tomas Chivato, Gunter J. Sturm, André Moreira, Mubeccel Akdis, Barbara Rogala, Ludger Klimek, Ioana Agache, María José Torres, Marek Jutel, Matteo Bonini, Radoslaw Gawlik, Jolanta Walusiak-Skorupa, Marina Atanaskovic-Markovic, Montserrat Alvaro, Stefan Vieths, Stefano Del Giacco, Sarita Patil, Alexandra F. Santos, A. Cianferoni, Charlotte G. Mortz, Antonino Romano, Giorgio Walter Canonica, Sergio Bonini, Antti Lauerma, Hideaki Morita, Knut Brockow, and Frédéric De Blay

Subjects
Allergen immunotherapy, medicine.medical_specialty, Allergy, biology, business.industry, Immunoglobulin E, medicine.disease, Vaccination, Immune system, Pandemic, biology.protein, medicine, In patient, Intensive care medicine, business, Asthma
Abstract

Immune modulation is a key therapeutic tool for allergic diseases and asthma. It can be achieved in an antigen-specific way via allergen immunotherapy (AIT) or in endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: IgE, IL-5 and IL-4/IL-13. COVID-19 vaccine provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. It works as well through immune modulation. Thus, as there is an obvious interference between these treatment modalities recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) gathered an outstanding expert panel under its Research and Outreach Committee (ROC). This expert panel was called to evaluate the evidence and formulate recommendation on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.

Published
2021
Full Text
View/download PDF

2. Vaccines and Allergic reactions: the past, the current COVID-19 pandemic, and future perspectives

Author

Menno C. van Zelm, Wytske Fokkens, Oscar Palomares, Sharon Chinthrajah, Mihir Shah, Liam O'Mahony, Oliver Pfaar, Katie Fast, Grace Rabinowitz, Robyn E O'Hehir, Surabhi Jain, Ioana Agache, Domingo Barber Hernández, Ronald L. Rabin, De Yun Wang, Tomas Chivato, Kari C. Nadeau, María José Torres, Milena Sokolowska, William Collins, Thomas Eiwegger, Carmen Riggioni, Zuzana Diamant, Markus Ollert, Luo Zhang, Vanitha Sampath, Claudia Traidl-Hoffmann, Cezmi A. Akdis, Milos Jesenak, Mohamed H. Shamji, and Stefan Vieths

Subjects
Vaccination, Safety profile, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Vaccine manufacturing, Infectious disease (medical specialty), business.industry, Public health, Incidence (epidemiology), Pandemic, medicine, Intensive care medicine, business
Abstract

Vaccines are essential public health tools with a favorable safety profile and prophylactic effectiveness that have historically played significant roles in reducing infectious disease burden in populations, when the majority of individuals are vaccinated. The COVID-19 vaccines are expected to have similar positive impacts on health across the globe. While serious allergic reactions to vaccines are rare, their underlying mechanisms and implications for clinical management should be considered to provide individuals with the safest care possible. In this review, we provide an overview of different types of allergic adverse reactions that can potentially occur after vaccination and individual vaccine components capable of causing the allergic adverse reactions. We present the incidence of allergic adverse reactions during clinical studies and through post-authorization and post-marketing surveillance and provide plausible causes of these reactions based on potential allergenic components present in several common vaccines. Additionally, we review implications for individual diagnosis and management and vaccine manufacturing overall. Finally, we suggest areas for future research.

Published
2021
Full Text
View/download PDF

4. Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases

Author

Zuzana Diamant, Stefano Del Giacco, Francesco Branca, Mohamed H. Shamji, Oscar Palomares, Montserat Alvaro-Lozano, Isabel Skypala, Isabella Annesi-Maesano, O. Spranger, Leyla Namazova-Baranova, Cevdet Ozdemir, Frank Ingenrieth, Zlatko Fras, Glennis Scadding, Susanne Lau, Antonio Spanevello, Stefan Vieths, Andreas Bonertz, Arzu Yorgancioglu, Oliver Pfaar, Liam O'Mahony, Tomas Chivato, Peter Schmid-Grendelmeier, Ibon Eguiluz-Gracia, Karin Hoffmann-Sommergruber, Roy Gert van Wijk, Monica Spinola, Carsten B. Schmidt-Weber, Peter Hellings, Domingo Barber Hernández, Mikaela Odemyr, Marek Jutel, María Luisa de Torres, Anke Graessel, Joaquín Sastre, José María Olaguibel, Andrew J. Cant, Andrea Vereda, Philippe Gevaert, Ioana Agache, Sergio Bonini, Antti Lauerma, Internal Medicine, University of Helsinki, Department of Dermatology, Allergology and Venereology, University Management, HUS Inflammation Center, Transylvania University, Brasov, Romania, Department of Epidemiology of Allergic and Respiratory Diseases, Medical School Saint Antoine, IPLESP, INSERM and Sorbonne Université, Paris, France, Federal Agency for Vaccines and Biomedicines, Paul-Ehrlich-Institut, Langen, Germany, Department of Nutrition for Health and Development, Geneva, Switzerland, WHO/HQ, Geneva, Switzerland, University of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom, European Society for Immunodeficiencies, Geneva, Switzerland, Division of Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia, UEMS - Union Europeenne des Medecins Specialistes/European Union of Medical Specialists, Brussels, Belgium, SCOPE Europe, Bruxelles, Belgium, Department of Pediatrics, Russian National Research Medical University of MoH RF, Moscow, Russian Federation, Department of Pediatrics, Central Clinical Hospital of MoSHE (Ministry of Science and High Education), Moscow, Russian Federation, European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), Brussels, Belgium, Dipartimento di Medicina e Chirurgia, Malattie dell'Apparato Respiratorio, Università degli Studi dell'Insubria, Varese – Como, Italy, Dipartimento di Medicina e Riabilitazione Cardio Respiratoria, U.O. di Pneumologia Riabilitativa, Istituti Clinici Scientifici Maugeri, IRCCS Tradate, Tradate, Italy, Department of Pulmonology, Celal Bayar University School of Medicine, Manisa, Turkey, Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain, Department of Basic Medical Sciences, School of Medicine, Universidad CEU San Pablo, Madrid, Spain, RETIC ARADYAL RD16/0006/0015, Instituto de Salud Carlos III, Madrid, Spain, School of Medicine, University CEU San Pablo, Madrid, Spain, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, Department of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden, Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic, Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain, ARADyAL Network RD16/0006/0001, Carlos III Health Institute, Madrid, Spain, Section of Allergology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands, Department of Otorhinolaryngology-Head and Neck Surgery, Upper Airways Research Laboratory, Ghent University, Ghent, Belgium, Allergy Therapeutics, Worthing, United Kingdom, Bencard Allergie GmbH, Munich, Germany, Department of Otorhinolaryngology-Head and Neck Surgery, UZ Leuven, Leuven, Belgium, Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, Netherlands, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria, Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland, 'ALL-MED' Medical Research Institute, Wroclaw, Poland, Department for Pediatric Pneumology, Immunology and Intensive Care, Charité Universität Medizin, Berlin, Germany, Dermatology and Allergology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, Severe Asthma Unit, Complejo Hospitalario de Navarra, Pamplona, Spain, Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland, Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkey, Department of Pediatrics, Division of Pediatric Allergy & Immunology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany, Department of Allergy, Fundación Jimenez Diaz, Madrid, Spain, Department of Medicine, Instituto Carlos III, CIBERES, Universidad Autónoma de Madrid, Madrid, Spain, RNTNE Hospital, London, United Kingdom, Zentrums Allergie & Umwelt (ZAUM), Technische Universität und Helmholtz Zentrum, München, Germany, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland, Christine-Kühne Center for Allergy Research and Education CK-CARE Davos, Davos, Switzerland, Allergy & Clinical Immunology, Inflammation, Repair and Development, Imperial College, National Heart and Lung Institute, Immunomodulation and Tolerance Group, London, United Kingdom, Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom, Imperial College, London, United Kingdom, European Medical Affairs, Sanofi, Milan, Italy, Global Allergy and Asthma Patient Platform, Vienna, Austria, Aimmune Therapeutics, London, United Kingdom, Institute of Translational Pharmacology, Italian National Research Council, Rome, Italy, and Ear, Nose and Throat

Subjects
Big Data, 0301 basic medicine, Clinical immunology, quality criteria, Big data, exposome, environmental health, GUIDELINES, FOOD ALLERGY, Capital Financing, Translational Research, Biomedical, 0302 clinical medicine, White paper, asthma, PRECISION MEDICINE, big data, Immunology and Allergy, 0303 health sciences, implementation science, Health Policy, Disease Management, ASSOCIATION, Public relations, 3. Good health, Europe, OPPORTUNITIES, allergic diseases, translational research, Information Technology, Exposome, BIRTH, Immunology, BIOMARKERS, Bioengineering, Context (language use), Translational research, RM1-950, Asthma care, 03 medical and health sciences, Drug Development, Political science, Hypersensitivity, Humans, DRUG DEVELOPMENT, 030304 developmental biology, business.industry, Research, Information technology, Precision medicine, 030104 developmental biology, 030228 respiratory system, 13. Climate action, 3121 General medicine, internal medicine and other clinical medicine, Therapeutics. Pharmacology, Patient Participation, business, Medical ethics
Abstract

The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2019
Full Text
View/download PDF

5. Could Profilin Be a 'Canary in a Coal Mine' of the Increasing Allergy Epidemic?

Author

Domingo Barber Hernández

Subjects
Male, Allergy, biology, business.industry, Immunology, Coal mining, General Medicine, Allergens, Antigens, Plant, Immunoglobulin E, medicine.disease, Profilins, Profilin, medicine, biology.protein, Hypersensitivity, Immunology and Allergy, Humans, Pollen, Female, business, Plant immunology
Published
2015

6. Managing food allergy: GA2LEN guideline 2022

Author

Antonella Muraro, MD, Debra de Silva, PhD, Susanne Halken, DM DMSc, Margitta Worm, MD∗, Ekaterina Khaleva, MD MSc, Stefania Arasi, MD PhD, Audrey Dunn-Galvin, PhD, Bright I. Nwaru, PhD, Nicolette W. De Jong, PhD, Pablo Rodríguez Del Río, MD PhD, Paul J. Turner, FRCPCH PhD, Pete Smith, FRACP PhD, Philippe Begin, MD MSc, Elizabeth Angier, MSc, Hasan Arshad, DM, Barbara Ballmer-Weber, PhD, Kirsten Beyer, MD, Carsten Bindslev-Jensen, MD PhD DSc, Antonella Cianferoni, MD PhD, Céline Demoulin, Antoine Deschildre, MD, Motohiro Ebisawa, MD PhD, Maria Montserrat Fernandez-Rivas, DM PhD, Alessandro Fiocchi, MD, Bertine Flokstra-de Blok, PhD, Jennifer Gerdts, Josefine Gradman, MD, Kate Grimshaw, PhD, Carla Jones, Susanne Lau, MD, Richard Loh, FRACP, Montserrat Alvaro Lozano, MD, Mika Makela, MD PhD, Mary Jane Marchisotto, Rosan Meyer, PhD, Clare Mills, PhD, Caroline Nilsson, MD PhD, Anna Nowak-Wegrzyn, MD PhD, Ulugbek Nurmatov, PhD, Giovanni Pajno, MD, Marcia Podestà, Lars K. Poulsen, PhD, Hugh A. Sampson, MD, Angel Sanchez, Sabine Schnadt, Hania Szajewska, MD, Ronald Van Ree, PhD, Carina Venter, PhD, Berber Vlieg-Boerstra, PhD, Amena Warner, Gary Wong, MD FRCPC, Robert Wood, MD, Torsten Zuberbier, MD, Graham Roberts, DM, Priya Bansal, Roberto Berni–Canani, Katharina Blumchen, Andreas Bonertz, Melisande Bourgoin-Heck, Ozlem Ceylon, Amandine Divaret-Chauveau, David Fleischer, Maximiliano Gomez, Marion Groetch, Domingo Barber Hernandez, Betina Hjorth, Lydia Collins Hussey, André C. Knulst, Agnes Leung, Douglas Mack, Vera Mahler, Francesca Mori, Leyla Namazova-Baranova, Kati Palosuo, Claudio Alberto Salvador Parisi, Antonio Carlos Pastorino, Odilija Rudzeviciene, Maria Said, Piotr Sawiec, Scott Sicherer, Sakura Sato, and Svitlana Zubchenko

Subjects
Food allergy, Food hypersensitivity, Children, Adolescent, Adults, Immunologic diseases. Allergy, RC581-607
Abstract

Food allergy affects approximately 2–4% of children and adults. This guideline provides recommendations for managing food allergy from the Global Allergy and Asthma European Network (GA2LEN). A multidisciplinary international Task Force developed the guideline using the Appraisal of Guidelines for Research and Evaluation (AGREE) II framework and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. We reviewed the latest available evidence as of April 2021 (161 studies) and created recommendations by balancing benefits, harms, feasibility, and patient and clinician experiences. We suggest that people diagnosed with food allergy avoid triggering allergens (low certainty evidence). We suggest that infants with cow's milk allergy who need a breastmilk alternative use either hypoallergenic extensively hydrolyzed cow's milk formula or an amino acid-based formula (moderate certainty). For selected children with peanut allergy, we recommend oral immunotherapy (high certainty), though epicutaneous immunotherapy might be considered depending on individual preferences and availability (moderate certainty). We suggest considering oral immunotherapy for children with persistent severe hen's egg or cow's milk allergy (moderate certainty). There are significant gaps in evidence about safety and effectiveness of the various strategies. Research is needed to determine the best approaches to education, how to predict the risk of severe reactions, whether immunotherapy is cost-effective and whether biological therapies are effective alone or combined with allergen immunotherapy.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results